Genetic testing can help physicians better understand an individual’s AML and guide treatment decisions. So which genetic tests should AML patients have and when? Get the answers during a live, one-hour webinar on Monday, October 30 at 12 pm Pacific (2 pm Central; 3 pm Eastern), produced in partnership with the Patient Power and The Leukemia & Lymphoma Society (LLS). Register now to watch live or get access to the replay afterwards. During the webinar, you’ll hear from a panel of experts, including leading AML specialists and a powerful patient advocate. There will also be a question-and-answer session so send in your questions now to questions@patientpower.info.
Our expert panel will discuss:
- The most common genetic mutations
- How certain mutations can impact your treatment options
- What genetic tests are currently available
- How you can work with your healthcare team to ensure you get the right tests at the right time
Join us to learn more about genetic tests so you and your loved one can be informed and empowered when making treatment decisions.
Once you register, you will receive a confirmation email with details for joining the program at the scheduled time.
We thank Astellas, Celgene Corporation, Novartis, Pfizer and Seattle Genetics for their support.
